Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant \u3cem\u3eStaphylococcus aureus\u3c/em\u3e Strains by Yamaki, Jason et al.
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
7-1-2013
Tigecycline Induction of Phenol-Soluble Modulins
by Invasive Methicillin-Resistant Staphylococcus
aureus Strains
Jason Yamaki
Chapman University, yamaki@chapman.edu
Timothy Synold
City of Hope Medical Center
Annie Wong-Beringer
University of Southern California
Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Bacteria Commons, and the Other
Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Yamaki J, Synold T, Wong-Beringer A. Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant
Staphylococcus aureus Strains. Antimicrobial Agents and Chemotherapy. 2013;57(9):4562-4565. doi:10.1128/AAC.00470-13.
Tigecycline Induction of Phenol-Soluble Modulins by Invasive
Methicillin-Resistant Staphylococcus aureus Strains
Comments
This article was originally published in Antimicrobial Agents and Chemotherapy, volume 57, issue 9, in 2013.
DOI: 10.1128/AAC.00470-13
Copyright
American Society for Microbiology
This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/504
Tigecycline Induction of Phenol-Soluble Modulins by Invasive
Methicillin-Resistant Staphylococcus aureus Strains
Jason Yamaki,a Timothy Synold,b Annie Wong-Beringera,c
University of Southern California, Los Angeles, California, USAa; City of Hope Medical Center, Duarte, California, USAb; Huntington Hospital, Pasadena, California, USAc
We examined the effects of tigecycline on three types of exoproteins, -type phenol-soluble modulins (PSM1 to PSM4), -he-
molysin, and protein A, in 13 methicillin-resistant Staphylococcus aureus isolates compared to those of clindamycin and lin-
ezolid. Paradoxical increases in PSMs occurred in 77% of the isolates with tigecycline at 1/4 and 1/8 MICs and clindamycin at
1/8 MIC compared to only 23% of the isolates with linezolid at 1/8 MIC. Induction was specific to PSM1 to PSM4, as protein A
and -hemolysin production was decreased under the same conditions by all of the antibiotics used.
Methicillin-resistant Staphylococcus aureus (MRSA) virulencein pneumonia and bacteremia has been attributed to exo-
proteins, specifically, -hemolysin (Hla) and -type phenol-sol-
uble modulins (PSM1 to PSM4), which are produced by nearly
all S. aureus strains and in excess by community-acquired MRSA
strains (1). These exoproteins not only cause direct damage to
target host cells but also exacerbate the host inflammatory re-
sponse, contributing to acute lung injury. Additionally, recent re-
ports have demonstrated the importance of protein A (Spa) in
invasive diseases such as pneumonia (2, 3).
In light of the impressive arsenal of virulence factors contrib-
uting to the success of MRSA as a pathogen, it is of keen interest to
determine if anti-MRSA agents belonging to the antibiotic class of
protein synthesis inhibitors provide the added antivirulence ben-
efit of exoprotein inhibition. In the present study, we investigated
the antivirulence potential of tigecycline, linezolid, and clindamy-
cin which have been proven efficacious in the treatment of MRSA
infections. Our goal was to determine whether antivirulence ef-
fects can be generalized across different clinical isolates, different
agents that inhibit protein synthesis, and different exoproteins.
Specifically, we tested the effects of the above three antibiotics at
subinhibitory concentrations on formylated PSM1 to PSM4,
Hla, and Spa production by invasive MRSA isolates.
Eleven invasive MRSA isolates were tested under the following
conditions. A modified CLSI broth macrodilution assay was used
to determine MICs after 24 h of incubation at 37°C and shaking at
250 rpm in tryptic soy broth. Supernatants were then analyzed by
liquid chromatography-tandem mass spectrometry, and Hla and
Spa were analyzed by Western blotting as previously described (4,
5). Measured exotoxin values were normalized to the cell optical
density at 600 nm (OD600) at the time the supernatant was har-
vested. PSM concentrations under various test conditions were
compared by analysis of variance with Dunn’s correction using
GraphPad Prism version 5.0 software (GraphPad, San Diego, CA).
Table 1 depicts the SCCmec type, PVL status, and baseline
PSM production characteristics of the 13 isolates studied (11
clinical isolates and two control strains). The PSM1 to PSM4
peptides have been shown to cause concentration-dependent neu-
trophil lysis (6, 7). A PSM3 concentration of 5 g/ml has been
shown to lyse nearly 50% of human polymorphonuclear neutro-
phils (PMNs), while 10 g/ml of PSM1 and PSM4 can cause
60% and 10% PMN lysis, respectively (8, 9). Thus, isolates were
grouped on the basis of the amount of the most potent peptide,
PSM3, produced at the baseline as very low to low (5 g/ml),
medium (6 to 15 g/ml), or high (15 g/ml) producers.
Bacterial growth at 1/2 MICs of all three antibiotics was altered
in half of the isolates tested by as much as 50% of the final OD
compared to a no-antibiotic control, while no significant differ-
ence in the growth of any isolates was observed at 1/4 and 1/8
MICs. Thus, subsequent discussions will focus on the effect of
antibiotics at the latter subinhibitory concentrations that did not
affect growth. Measured PSM values were normalized to the
OD600 at the time the supernatant was harvested.
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TABLE 1 Characteristics of the 11 clinical isolates and two control
strains used in this study
Isolate or strain
mec
type PVLa Infection type
PSMb
baseline
MIC (g/ml)c
TYG CL LZ
1 IV  Blood Low 0.125 0.188 3
2 IV  Blood Medium 0.125 0.25 3
3 IV  Blood Low 0.125 0.188 2
4 IV  Blood Medium 0.125 0.25 2
5 IV  Blood Medium 0.125 0.188 2
6 IV  Pneumonia Low 0.188 0.125 2
7 IV  Pneumonia Medium 0.125 0.188 3
8 IV  Necrotizing
pneumonia
High 0.125 0.25 3
9 II  Pneumonia Very low 0.125 256 3
10 II  Pneumonia Very low 0.125 256 1
11 II  Pneumonia Very low 0.125 0.188 2
Control strains
USA300 (LAC) IV  Wound Medium 0.25 0.25 2
USA600 II  Blood Low 0.125 256 2
a A plus or minus sign denotes the presence or absence, respectively, of the lukF/S gene,
which encodes the Panton-Valentine leukocidin.
b The PSM3 production level at the baseline was arbitrarily defined as very low (1
g/ml), low (1 to 5 g/ml), medium (6 to 15 g/ml), or high (15 g/ml).
c TYG, tigecycline; CL, clindamycin; LZ, linezolid. Resistance is defined as a MIC of
256 g/ml (not tested for PSM production at subinhibitory concentration).
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Tigecycline appears to have the least inhibitory potential over-
all, while linezolid has the greatest (Fig. 1a to c). Increased pro-
duction of all four PSM peptides was the primary response ob-
served in the presence of tigecycline at 1/4 and 1/8 MICs, while
with clindamycin this occurred only at 1/8 MIC (Fig. 1b and c).
Notably, compared to clindamycin at 1/8 MIC, which significantly
induced PSM production in seven isolates, linezolid at 1/8 MIC
modestly induced PSM production in only three isolates (Fig. 1a).
Strain-specific responses to the presence of subinhibitory an-
tibiotic concentrations in PSM production were observed. Drug
concentrations that induced PSM production in some isolates
did not do so in others, independently of the baseline production
level. Specifically, with tigecycline at both 1/4 and 1/8 MICs (Fig.
1d), PSM1 was induced at least 1.5 times above the baseline in
77% (11/13) of the isolates, while induction did not occur in two
isolates at any of the concentrations tested. Similar results were
observed with clindamycin, where 54% (7/13) of the isolates were
induced by greater than 150%; however, this was observed only at
1/8 MIC. In those isolates, PSM1 production was induced to
greater than 10 g/ml, which has been shown to cause significant
PMN lysis (9). Linezolid at the same concentration resulted in
increases in PSM1 in only 23% (3/13) of the isolates tested, was
inhibitory in 5 isolates, and had no significant effects on the re-
maining isolates. Of additional interest is the observation that
nonproducers at the baseline produced PSM peptides in the
presence of subinhibitory concentrations of both linezolid and
tigecycline. However, it is noteworthy that PSM production that
was induced in those two isolates did not exceed 4 g/ml and thus
would not be expected to have a significant impact on host PMNs.
In contrast to results observed with the PSM1 to PSM4 pep-
tides, we found that the production of both Hla and Spa did not
increase under any condition and was inhibited in a dose-depen-
dent manner at the concentrations of all three antibiotics tested
regardless of whether PSM peptides were induced or suppressed
in those isolates (Fig. 2).
To our knowledge, we are the first to investigate the effect of
tigecycline on MRSA PSM1 to PSM4 peptide production. We
also included clindamycin and linezolid for comparison and
tested their antivirulence potential against two other key exotox-
ins, Hla and Spa. We found that at sub-MICs, agents in this class of
antibiotics have pleiotropic effects on toxin production that are
dependent on the drug, strain, and toxin tested.
All three of the antibiotics tested are known to have large vol-
umes of distribution and would be expected to be present at high
concentrations within tissues. However, the concentrations tested
reflect clinical scenarios where sub-MICs might be achieved at
sites of infection because of inadequate dosing, altered pharmaco-
kinetic parameters of the patient, and differential drug distribu-
tion to various body sites. Specifically, compared to the concen-
trations achieved at other body sites, tigecycline achieves relatively
low levels in serum (0.11 to 0.19 g/ml) and lung epithelial lining
fluid (0.11 to 0.31 g/ml), which are relevant to bacteremia and
FIG 1 Overall effects of linezolid, clindamycin, and tigecycline on PSM1 to PSM4 production. (a to c) Effects of antibiotics on the production of PSM1 to
PSM4 (1, 2, 3, and 4, respectively). All measured PSM values (g/ml) were normalized to OD600 and then calculated as percentages relative to the baseline.
Isolates (n  10) included only those that produced measureable PSM peptides at the baseline (***, P  0.0001; **, P  0.001; *, P  0.05). (d) Strain-to-strain
variability of PSM1 production at 1/8 MIC of tigecycline (TYG). Strains were grouped according to their baseline PSM1 production as very low (1 g/ml),
low (1 to 5 g/ml), medium (6 to 15 g/ml), and high (15 g/ml) producers.
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pneumonia, respectively, which are below the 0.5-g/ml FDA
MIC breakpoint of S. aureus susceptibility (10–12).
Low concentrations (1/4 and 1/8 MICs) of the antibiotics
tested were more likely to induce PSM production overall, with
tigecycline having the greatest induction potential, clindamycin
having less, and linezolid even less than that. Furthermore, the
magnitudes of induction and inhibition differed among isolates,
where the same drug could induce PSM production in one iso-
late while inhibiting production in another. The observation of
PSM induction by protein synthesis-inhibiting antibiotics (e.g.,
linezolid and clindamycin) at sub-MICs is contrary to published
literature on other exotoxins, where studies have consistently
found toxin suppression under this class of antibiotics (13–16).
The production of both Hla and Spa was suppressed by antibiotics
tested at subinhibitory concentrations among the study isolates,
independently of whether PSM was induced in the same isolates.
Hence, our results indicate that the induction effects may be spe-
cific for PSM peptides. In contrast to our findings where signif-
icant inhibition was observed, a recent article showed tigecycline
to be minimally inhibitory of Hla and Spa production (17); how-
ever, this difference may be due to the different strains and testing
methods used.
Our study has several limitations. First, while we accounted for
changes in cell counts by normalizing the amount of toxin mea-
sured to CFU counts, other factors, such as initial slowing of
growth, could also affect toxin production. In addition, our ob-
servations are strictly in vitro and may not reflect how MRSA
strains express virulence in the host environment, where the ef-
fects of toxin induction may be mitigated by host defenses that are
present.
Further investigation is needed to examine if any other major
toxins are induced, as PSM peptides did when exposed to sub-
inhibitory concentrations of different antibiotics. Elucidating the
mechanism that underlies the induction of PSM peptides is of
great interest and has implications for the future development of
new antibiotics. In light of the recent evidence implicating tigecy-
cline in excess deaths and treatment failure in severe infections
(18), the enhanced toxin production observed in this study may
have clinical relevance and deserves further study. For now, our
data caution against the general assumption by clinicians that all
protein synthesis inhibitors possess inhibitory potential against all
of the exotoxins produced by S. aureus and affirm the importance
of adequate dosing.
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